Articles On Race Oncology (ASX:RAC)

  Southside Cancer Care Centre in Miranda initiated as first site for Race’s Phase I trial of RC220 in advanced solid tumours Race awaiting governance approval to activate site for patient recruitment Up to 53 patients to be enrolled in op...

Opthea shares enter trading halt on St Patrick’s Day ahead of a “material” trial update Imricor is on the hunt for funds, reportedly up to $80 million Race Oncology is in pole position for phase I trial start In the diabolically difficult...

Highlights: Opthea initiates a trading halt ahead of phase III clinical trial updates. Imricor Medical Systems advances funding efforts for US market entry. Race Oncology secures ethics approval for phase I trial of anti-can...

ASX bounces back with miners leading the charge US shutdown fears ease, giving markets a lift Myer and Liontown shine as big movers on the ASX   The ASX bounced back on Friday, shaking off a three-day losing streak and finishing 0.52% hig...

Bellberry Human Research Ethics Committee approves a Phase I trial of RC220 bisantrene in adult solid tumour patients Lead clinical site Southside Cancer Care Centre will start enrolling patients this month pending institutional approval a...

The ASX has been up as much as 0.45% at 7,783 points, breaking its Week 11 losing streak on the back of a rally in gold stocks. Materials has been the best performing sector, up 1.85%, followed by Utilities, up 1.4%, and Industrials, up...

Race Oncology Ltd (ASX:RAC) has been approved for its Phase One trial of its chemotherapeutic candidate RC220 to treat people with solid tumours. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest he...

Good afternoon and welcome to HotCopper’s Market Close, I’m Jonathon Davidson. Doldrums remained the quo on Wednesday as tariff uncertainty once again shakes markets. The ASX pared some losses midday, perhaps because Trump’s congress spe...

Race executes work order contract with George Clinical to support Phase 1 trial of anticancer treatment RC220 Total cost of work order ~$8.6 million, with final trial cost to depend on number of recruited patients and other trial variables...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

ASX healthcare leaders are often involved in multiple companies or organisations  Syntara CEO Gary Philips believes seasoned executives can help develop the sector in Australia Dimerix CEO and MD Dr Nina Webster has two other key positions...

Highlights: Fisher & Paykel Healthcare (ASX:FPH) faces new tariffs but is adapting with strategic measures. Orthocell (ASX:OCC) is progressing with regulatory approvals in multiple markets. Life-sciences...

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Fraser Palamara takes a look at Race Oncology (ASX:RAC), a biopharmaceutical...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

ASX gives back gains ahead of Fed decision Vulcan and DigiCo rise MinRes completes $780m gas deal with Hancock Prospecting   The ASX gave back its earlier gains this afternoon as investors adopted a more cautious approach ahead of the US...

Race Oncology has appointed experienced biotech executive Dr Megan Baldwin as a non-executive director Baldwin has more than 25 years’ experience in therapeutic drug development for oncology and opthalmology She is the founder and chief in...

ASX rises as banks lead, energy lags Bitcoin hits $107k… $150k target murmurings grow louder  Orica CEO to retire, Data#3 tumbles on Microsoft news   The ASX edged higher by 0.78% on Tuesday, with the big banks keeping the mood upbeat thr...

Vulcan Energy Resources Ltd (ASX: VUL) shares have returned from their trading halt on Friday with a thud. In morning trade, the ASX lithium stock's shares are down 12% to $5.82. Why is this ASX lithium stock crashing? The weakness in the V...

One ASX lithium stock refused to budge while the S&P/ASX 300 Index (ASX: XKO) limped lower today. Australian shares largely followed the mediocre example set by US markets last night. However, shares in Vulcan Energy Resources Ltd (...

It’s been tough going for the ASX on Friday ahead of key US jobs report Bitcoin cooled off after record highs as profit-taking hit APA was up on pipeline news; Iluka slumped on cost blowout   After hitting fresh record highs earlier this...

Race submits human ethics regulatory package for phase I trial in solid tumour patients using RC220 bisantrene Up to 10 additional sites set to follow the first trial site with patient recruitment expected to start in Q1 CY25 Phase I study...

The ASX200 closed up 0.15% at 8,474 points. Bitcoin broke through US$100,000 for the very first time after climbing 6.9%. The OG cryptocurrency is now much more accessible, given the advent of crypto ETFs – and this is perhaps contributi...

Three ASX biotech shares are setting the bar high today. The companies have grabbed investor interest today, with each releasing promising news. And this is sending them racing ahead of the 0.2% gains posted by the All Ordinaries Index (...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

An Australian biotech that counts former Macquarie Group Ltd (ASX: MQG) CEO Allan Moss and Platinum Asset Management fund among its shareholders is planning an ASX initial public offering (IPO) next year. According to The Australian, Ha...

If you have room in your portfolio for some new additions, then it could be worth listening to what Goldman Sachs is saying about the ASX 300 stocks in this article. That's because the broker has just put buy ratings on both stocks this mor...

Stockhead’s Fraser Palamara sits down with Race Oncology’s (ASX:RAC) CEO Dr Daniel Tillett to get the short end of the long story on the company’s latest news. The biopharmaceutical company has successfully completed an FTO-targeted drug di...

It was a disappointing day for the S&P/ASX 200 Index (ASX: XJO) this Thursday, with the index giving up an early lead this morning to close lower. By the time the markets closed, t...

Knee-jerk reactions by speculators are often ripe for producing long-term, money-making investments. I think I've found an ASX 300 stock that fits the bill. The stock market is full of emotions. In the words of the OG value investor, Be...

ASX healthcare shares are currently in the red on Thursday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) down 0.2% and the broader S&P/ASX 200 Index (ASX: XJO) 0.18% lower. However, two ASX healthcare shares are bucking...

The ASX200 has been down 0.1% at 8,317 points. The local bourse pared early gains and has been trading flat in the afternoon. The brent crude oil price has steadied at around US$73 per barrel as US crude stockpiles grow for the third...

So… I'm sitting on a plane, on the way to the Gold Coast for a company meeting (three cheers for in-flight Wi-Fi!). I'm really looking forward to it – we all work mostly or completely from home, so a whole-group get together is unusual....

The S&P/ASX 200 Index (ASX: XJO) has run out of steam in afternoon trade and slipped into the red. At the time of writing, the benchmark index is down slightly to 8,325.5 points. Four ASX shares that are not letting that hold them bac...

Race Oncology Ltd’s (ASX:RAC) now-completed drug discovery program, run at Melbourne’s Monash University, allows it to identify 39 unique molecules which bind to – and have the potential to inhibit – a protein associated with cancers. Th...

Highlights    Enhanced understanding of SCLC subtypes drives tailored treatment approaches.   Immunotherapy and antibody-drug conjugates emerge as key strategies.   Asia-Pacific region identified as a critical area for further clinica...

Amid improving sector sentiment, Actinogen says its Alzheimer’s trial is off to a flier Telix shares start trading on the Nasdaq tonight More of the Trump-edelic effect? Tryptamine shares are on a roll   Actinogen Medical (ASX:ACW) report...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

  Tryptamine receives firm commitments to raise $6m in placement strongly supported by new and existing stakeholders Placement cornerstoned by Merchant Biotech Fund and biotech investor Dr Daniel Tillett, who will join the board Funds to...

In this interview Dale Gillham and small cap company director Rod North discuss what to look for in microcap stocks and what place they should have in an investor’s portfolio. They discuss success stories, risk vs reward, and, the challe...

Race Oncology (ASX:RAC) has completed its Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine for the treatment of relapsed or refractory acute myeloid leukaemia (AML). AML is a type of cancer that starts in the b...

  ASX 200 index falls despite gains in energy stocks Smaller oil and gas firms benefit from rising crude prices Iron ore stocks drop as prices retreat   The ASX 200 index fell hard on Friday, down by 0.75%, despite some gains in the Ener...

    ASX edges down in a quiet market Pilbara Minerals falls 5pc as share block sale is reported Westpac sells auto finance unit for up to $1.6 billion   The ASX has lifted slightly on Thursday, up by 0.1%, as traders remain cautious amid...

Island Pharmaceuticals undertakes a $3.5m capital raise strongly supported by cornerstone investors All subjects dosed in the Phase 2a component of Island’s Phase 2a/b PROTECT clinical trial for dengue fever The study capitalises on years...

Big biotech names support Island Therapeutics raising Radiopharm eyes FDA approval to start a therapeutic pan-cancer trial Truscreen’s cervical cancer diagnostic cracks a nice mention   Health Check is renowned biotech journo Tim Boreham’...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Stockhead joined with IR Department and Morgans for HealthInvest 2024 in Sydney last week The event highlighted some of ASX’s leading and up-and-coming biotech and life sciences companies Imricor Medical Systems, Race Oncology, Clarity Pha...

ASX health stocks dropped 1.74% in the past five days, while the broader markets rose 1.55% Power confident US Fed’s 50 basis points cut in cash rate this week will bring more optimism to the sector  Morgans, investor relations firm IR Dep...

ASX health stocks dropped 1.22% in the past four days, while the broader markets fell 1.35% Morgans downgrades Ramsay Health Care following its FY24 results, believes a ‘near-term earnings recovery looks challenging’ Percheron reports posi...

Stockhead’s Fraser Palamara sits down with new Race Oncology (ASX:RAC) executive chair Dr Peter Smith to get the short end of the long story on the company’s latest news. A board rework has been taken by investors in great stride, and Dr Sm...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...